WuXi Biologics has won six core awards of "CMO Leading Enterprise Award" for five consecutive years

In addition, WuXi Biologics also stood out in the "Capability" category this year for its leading end-to-end services such as an excellent integrated technology platform and sufficient production capacity, and won the title of "Champion"
.
The company empowers global partners with outstanding flexibility and flawless execution to benefit patients around the world

In the past 10 years or so, the "CMO Leading Enterprise Award" has been jointly awarded by American industry media Outsourced Pharma and Life Science Leader together with Industry Standard Research, a market research organization, mainly based on industry-oriented quality benchmark surveys
.
In the 2022 awards, pharmaceutical and biopharmaceutical companies of different sizes conducted a comprehensive evaluation of 23 indicators across more than 86 contract manufacturing service companies

"We are very honored to have won the six core awards of the 'CMO Leading Enterprise Award' for five consecutive years and won the 'Championship' in the 'Capability' category for the first time!" said Dr.
Zhisheng Chen, CEO of WuXi Biologics, "These two honors represent global customers.
The trust and confidence in us has once again demonstrated that we serve global customers with a world-class quality system, excellent execution, customer-centric flexibility and reliability
.
We will also continue to accelerate the empowerment of global partners to be efficient Research and develop biological drugs, help their products to be launched as soon as possible, and benefit the majority of patients

About WuXi Biologics

WuXi Biologics (stock code: 2269.

WuXi Biologics has more than 10,000 employees in China, the United States, Ireland, Germany and Singapore
.
With the professional service team of these employees, as well as outstanding technology and insight, the company provides customers with efficient and cost-effective biopharmaceutical solutions

WuXi Biologics regards environmental, social and governance (ESG) as an important part of business development and entrepreneurship, and is committed to becoming an ESG leader in the global biopharmaceutical CRDMO field, such as the application of greener next-generation biopharmaceutical technologies and Energy, etc.
lead the development of the industry
.
The company has established an ESG committee led by the CEO to fully implement the ESG strategy and fulfill its commitment to sustainable development

For more information, please contact

Media Relations

Investor Relations